Alkermes Plc at Citi BioPharma Conference (Virtual) Transcript
Good morning, everyone. Welcome to day 2 of our conference and to Alkermes fireside chat. I'm Navann Ty, I cover Spec Pharma at Citi, and I have the pleasure having Blair Jackson, EVP and COO of Alkermes; and Iain Brown, SVP and CFO. Maybe Blair and Iain, if you could start with a short introduction to Alkermes, it will be very helpful and then I could go to Q&A.
Sure. We'd be happy to. Thanks for the introduction. And maybe before I start, I'll just highlight that we will be making forward-looking statements, and so I encourage everyone to review our regulatory filings for a more full risk disclosure. But we really appreciate you having us at the conference. It's a little shocking that it's already September. It's been a crazy year for us. We've got a lot going on at the company. And it's really been a year focused on execution and execution across multiple lanes of the business. On the commercial side, driving the performance of our products,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
